BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.60% to $484.82 Monday, on what proved to be an all-around favorable ...

In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device, after clinical trial data showed the treatment did not ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $492.69, indicating a -1.96% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings ...

Vertex Pharmaceuticals Inc. closed 5.23% below its 52-week high of $519.88, which the company achieved on November 8th.